Abingdon Health PLC (GB:ABDX)
LSE:ABDX
Want to see GB:ABDX full AI Analyst Report?
ABDX Stock Chart & Stats
6.25 p
0.20 p(2.50%)
At close: 4:00 PM EST
6.25 p
0.20 p(2.50%)
Day’s Range― - ―
52-Week Range5.10 p - 13.00 p
Previous CloseN/A
Volume7.61K
Average Volume (3M)78.74K
Market Cap
£30.13M
Enterprise Value19.51M
Total Cash (Recent Filing)£3.71M
Total Debt (Recent Filing)£948.00K
Price to Earnings (P/E)―
Beta-0.10
Next Earnings
Nov 18, 2026EPS Estimate
<0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding251,077,850
10 Day Avg. Volume45,332
30 Day Avg. Volume78,736
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)4.84
Price to Sales (P/S)3.04
P/FCF Ratio-7.48
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)£12.18M
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthRevenue growth above 40% indicates durable expansion in demand for Abingdon's diagnostic products and services. Sustained top-line growth helps absorb fixed manufacturing costs, supports scale advantages, and can enable future margin recovery as volumes normalize over the next 2–6 months.
Contract Development & Manufacturing ModelA contract development and manufacturing business provides recurring, fee-based revenue and stickiness from regulatory qualification and technical know-how. These capabilities create higher switching costs for customers and a stable demand base beyond one-off product sales.
Manageable Leverage And Balanced Asset StructureRelatively low debt and a moderate equity ratio give the company financial flexibility to fund production scale-up or R&D without immediate refinancing pressure. Manageable leverage reduces insolvency risk and supports multi-quarter operational plans.
Bears Say
Negative Operating Cash FlowOperating activities consume cash despite positive FCF growth metrics, indicating the business currently fails to convert revenue into sustainable cash. Continued negative operating cash flow will likely require external financing or equity issuance to fund working capital and capex needs over months.
Weak Profitability & Declining Gross MarginNegative net profit and EBIT margins plus a falling gross margin point to structural cost or pricing pressure. Without margin stabilization, the company may struggle to generate internal funds for reinvestment, making profitability recovery a multi-quarter challenge.
Customer Concentration & Lumpy Order TimingReliance on a limited set of large contracts and lumpy manufacturing orders creates revenue and cashflow volatility. This structural exposure makes forecasting, capacity planning, and sustained utilization difficult, increasing the need for financial buffers or committed contracts.
Abingdon Health PLC News
ABDX FAQ
What was Abingdon Health PLC’s price range in the past 12 months?
Abingdon Health PLC lowest share price was 5.10 p and its highest was 13.00 p in the past 12 months.
What is Abingdon Health PLC’s market cap?
Abingdon Health PLC’s market cap is £30.13M.
When is Abingdon Health PLC’s upcoming earnings report date?
Abingdon Health PLC’s upcoming earnings report date is Nov 18, 2026 which is in 182 days.
How were Abingdon Health PLC’s earnings last quarter?
Abingdon Health PLC released its earnings results on Mar 17, 2026. The company reported -0.004 p earnings per share for the quarter, beating the consensus estimate of -0.006 p by 0.002 p.
Is Abingdon Health PLC overvalued?
According to Wall Street analysts Abingdon Health PLC’s price is currently Overvalued.
Does Abingdon Health PLC pay dividends?
Abingdon Health PLC does not currently pay dividends.
What is Abingdon Health PLC’s EPS estimate?
Abingdon Health PLC’s EPS estimate is <0.01.
How many shares outstanding does Abingdon Health PLC have?
Abingdon Health PLC has 251,077,850 shares outstanding.
What happened to Abingdon Health PLC’s price movement after its last earnings report?
Abingdon Health PLC reported an EPS of -0.004 p in its last earnings report, beating expectations of -0.006 p. Following the earnings report the stock price went down -3.03%.
Which hedge fund is a major shareholder of Abingdon Health PLC?
Currently, no hedge funds are holding shares in GB:ABDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Abingdon Health PLC
Abingdon Health PLC (ABDX) is a UK-based company specializing in the development and manufacture of rapid diagnostic tests. The company focuses on providing innovative solutions in the healthcare sector, particularly in the fields of infectious diseases, including COVID-19 testing, and other point-of-care testing applications. Abingdon Health aims to enhance patient outcomes through its high-quality, reliable diagnostics that are designed for use in various settings, ranging from hospitals to home testing.
Technical Analysis
Circassia Pharmaceuticals
―
EKF Diagnostics Holdings
―
Genedrive
―
Omega Diagnostics
―
Renalytix
―
Options Prices
Currently, No data available
---